Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Instil Bio Inc. (TIL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
11/13/2025: TIL (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $95.75
1 Year Target Price $95.75
| 2 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 248.31% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/13/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 101.19M USD | Price to earnings Ratio - | 1Y Target Price 95.75 |
Price to earnings Ratio - | 1Y Target Price 95.75 | ||
Volume (30-day avg) 4 | Beta 2.08 | 52 Weeks Range 10.80 - 42.79 | Updated Date 11/13/2025 |
52 Weeks Range 10.80 - 42.79 | Updated Date 11/13/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -12.91 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -12.86% | Return on Equity (TTM) -51.74% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 93172118 | Price to Sales(TTM) 55329.79 |
Enterprise Value 93172118 | Price to Sales(TTM) 55329.79 | ||
Enterprise Value to Revenue 43213.95 | Enterprise Value to EBITDA 0.62 | Shares Outstanding 6750716 | Shares Floating 3308053 |
Shares Outstanding 6750716 | Shares Floating 3308053 | ||
Percent Insiders 6.32 | Percent Institutions 70.1 |
Upturn AI SWOT
Instil Bio Inc.
Company Overview
History and Background
Instil Bio Inc. is a biopharmaceutical company focused on developing adoptive cell therapies for the treatment of cancer. Founded in 2018, it has grown through research and development efforts aimed at creating effective and accessible cell therapies.
Core Business Areas
- Adoptive Cell Therapy: Development and commercialization of genetically engineered tumor-infiltrating lymphocyte (TIL) therapies for solid tumors.
- Manufacturing and Technology: Advancement of manufacturing processes to improve the scalability and cost-effectiveness of TIL therapies.
Leadership and Structure
The leadership team consists of experienced executives in biotechnology and oncology. The organizational structure is based on research and development, clinical operations, and manufacturing.
Top Products and Market Share
Key Offerings
- ITIL-168 (Lifileucel): An autologous tumor-infiltrating lymphocyte (TIL) therapy being developed for the treatment of advanced melanoma and other solid tumors. The competition is significant from established immunotherapies, including checkpoint inhibitors from companies like Merck (Keytruda) and Bristol Myers Squibb (Opdivo). Market share is not yet applicable due to its clinical stage.
Market Dynamics
Industry Overview
The adoptive cell therapy market is rapidly growing, driven by advancements in immunotherapy and personalized medicine. There is high demand for effective cancer treatments, especially for solid tumors that are resistant to conventional therapies.
Positioning
Instil Bio is positioned as a leader in the development of next-generation TIL therapies, focusing on improving efficacy and accessibility. Their focus on solid tumors sets them apart from other cell therapy companies primarily targeting hematological malignancies.
Total Addressable Market (TAM)
The TAM for cell therapies in oncology is projected to reach billions of dollars. Instil Bio is targeting a segment of this market focused on solid tumors, with the goal of capturing a significant share through its innovative TIL platform.
Upturn SWOT Analysis
Strengths
- Proprietary TIL technology platform
- Experienced management team
- Focus on solid tumors
- Potential for durable responses in patients
Weaknesses
- High manufacturing costs
- Complex regulatory pathway
- Dependence on clinical trial success
- Limited commercial experience
Opportunities
- Expansion into new indications
- Partnerships with pharmaceutical companies
- Advancements in manufacturing technology
- Increasing adoption of cell therapies
Threats
- Competition from established therapies
- Regulatory hurdles
- Clinical trial failures
- Reimbursement challenges
Competitors and Market Share
Key Competitors
- BMY
- MRK
- ZIOP
Competitive Landscape
Instil Bio competes with established pharmaceutical companies offering checkpoint inhibitors and other immunotherapies. Its competitive advantage lies in its proprietary TIL technology and focus on solid tumors.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by progress in clinical trials and expansion of the research and development pipeline.
Future Projections: Future growth is dependent on successful clinical trial outcomes, regulatory approvals, and commercial launch of TIL therapies.
Recent Initiatives: Recent initiatives include advancing ITIL-168 through clinical trials, optimizing manufacturing processes, and expanding the pipeline with new TIL candidates.
Summary
Instil Bio is a clinical-stage biopharmaceutical company with a promising TIL technology platform focused on solid tumors. The company's success hinges on positive clinical trial outcomes and regulatory approvals for its lead candidate, ITIL-168. Challenges include high manufacturing costs and competition from established therapies. Its strong focus on innovation helps the company to keep pushing forward and innovating new and improved processes for their products
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company Filings
- Analyst Reports
- Industry Publications
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Instil Bio Inc.
Exchange NASDAQ | Headquaters Dallas, TX, United States | ||
IPO Launch date 2021-03-19 | Chairman & CEO Mr. Bronson Crouch | ||
Sector Healthcare | Industry Biotechnology | Full time employees 14 | Website https://instilbio.com |
Full time employees 14 | Website https://instilbio.com | ||
Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. Its lead products candidate is AXN-2510/IMM2510 that is in Phase 1b/2 clinical trial for the treatment of patients with chemotherapy in patients with advanced/metastatic non-small cell lung cancer. The company also conducts a Phase 1 open label trial in China for AXN-2510/IMM2510 as monotherapy in patients with advanced solid tumors, including triple-negative breast cancer, squamous non-small cell lung cancer, hepatocellular carcinoma, renal cell carcinoma, and rare solid tumors, such as soft tissue sarcomas and thymic cancer. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.